Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (68 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  V.TLT.WT | TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > Why is the company silent about Roswell?
View:
Post by RichieRich123 on Aug 12, 2020 10:47pm

Why is the company silent about Roswell?

what is the reason?

Is it Sheri's IP or ours?

SILENCE implies what???????

Anyone please - what would be the reason not to release this news?
Comment by StevenBirch on Aug 13, 2020 7:47am
What news? Stop trying to stir it up.
Comment by RichieRich123 on Aug 13, 2020 7:50am
What news?  re: Roswell. Thank you...you exactly made my point.
Comment by Longholder99 on Aug 13, 2020 8:04am
I dont even see these posts. Have had most of these names on 'ignore' for months. Works very nicely.
Comment by StevenBirch on Aug 13, 2020 10:45am
Good point, I guess I missed one.
Comment by Aubrey on Aug 13, 2020 4:03pm
Roswell Park/ Lumeda are testing TLD-433 on cancer cells. Since Theralase is the only source of THD-1433 they must have an agreement which is not yet material info. I noticed TLT ordered another batch of TLD-1433  at a cost of $1M  many months ago..so they either sold some to Lumeda for cash or they have bigger plans contingent on THD-1433  meeting Lumeda's needs. Lumeda had ...more  
Comment by goldn1 on Aug 13, 2020 4:32pm
Aub: I would think Roswell is material. If anything happened to that person whether it was TLD's fault, Theralase would be sued and these days everyone gets sued if there is a medical mishap. I don't know the answer, a long time ago Roger told me that either himself personally and TLT the company was on every patent, it is possible Sherri can use it for other purposes. I haven't ...more  
Comment by Aubrey on Aug 13, 2020 4:49pm
All I read was Lumeda testing TLD-433 .on a bench top... inviro on lung cancer cells. What else is going on? ..link? 
Comment by Quattro74 on Aug 13, 2020 6:53pm
I think the hope/speculation is that they might license 1433 or maybe do a phase 1 study using it, on their dime instead of TLTs.
Comment by Hempdoc on Aug 13, 2020 7:41pm
RPCCC really makes the perfect partner.  They are a top-notch & well-oiled research facility with well-lined pockets, thanks to lots of NCI/NIH/private funding.  For a small biotech like ours with a limited cash runway, it makes sense to take full advantage of making "many" TLD-1433 licensing deals with RP & similar facilities.  Let someone else who has an ...more  
Comment by Hempdoc on Aug 13, 2020 8:23pm
  Moving forward, I think a big boost to TLT's success would include forming more alliances/licensing opportunities with purely research/public health-based cancer centers (like a nonprofit RPCCC) where the pursuit of scientific excellence & improving community health drive the research, not profits.  Makes a lot of sense to me that we expand our ACT proof of concept & ...more  
Comment by skier59 on Aug 13, 2020 9:06pm
Yup, have to agree with all of that.....that would be a smart move. 
Comment by tdon1229 on Aug 14, 2020 1:12am
In the absence of any licensing agreement, it's not Theralase's place to report on what Roswell Park might be doing.  That's RP's place to report on their own activities ... or not report on it.  Theralase seemingly has all it can do to report on its own work.  it's not material until it's material.
Comment by Oilminerdeluxe on Aug 14, 2020 8:08am
That would be a nice thing to see something develop with Roswell. But when is probably impossible to say. Tomorrow, 2022, it could be a while. On the other hand, they must have played around withTLD-1433 for some time now
Comment by Hankerchief on Aug 14, 2020 9:46am
Roswell Park CC can really come out of this looking good.  If they move towards using xray/IV TLD 1433/Rutherrin it could open the door for a wide range of cancer types treated.  They seem to know what they are doing.  Get it done.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

View the Presentation

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 68 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250